- Home
- RMCO vs OTLK Comparison
RMCO vs OTLK Comparison
Compare RMCO & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCO | OTLK |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 38.7M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | RMCO | OTLK |
|---|---|---|
| Price | $3.95 | $0.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 41.3K | ★ 13.1M |
| Earning Date | 11-13-2025 | 02-13-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,798,352.00 | $1,413,535.00 |
| Revenue This Year | $531.90 | $1,578.49 |
| Revenue Next Year | $200.00 | $153.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 445.90 | N/A |
| 52 Week Low | $0.91 | $0.50 |
| 52 Week High | $4.76 | $3.39 |
Technical Indicators
Market Signals| Indicator | RMCO | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 66.17 | 26.47 |
| Support Level | $3.41 | $0.51 |
| Resistance Level | $4.43 | $0.56 |
| Average True Range (ATR) | 0.34 | 0.06 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 63.98 | 17.23 |
Price Performance
Historical ComparisonAbout RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.